Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
Holding EPIX?
Track your performance easily
EPIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $11.67
Previous Close$1.73
Volume188.70K
Average Volume (3M)815.46K
Market Cap
$78.99M
Enterprise Value-$53.15M
Total Cash (Recent Filing)$130.69M
Total Debt (Recent Filing)$342.14K
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Dec 10, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding44,368,959
10 Day Avg. Volume594,150
30 Day Avg. Volume815,461
Standard Deviation0.26
R-Squared0.13
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.94
Forecast
1Y Price Target
$1.85Price Target Upside4.52% Upside
Rating ConsensusHold
Number of Analyst Covering4
ESSA Pharma News
PremiumCompany Announcements
ESSA Pharma Advances Prostate Cancer Clinical TrialsBulls Say, Bears Say
Bulls Say
Financial PositionEPIX's robust cash balance of over $100M provides significant flexibility to explore new opportunities, particularly in the oncology space.
Oncology Drug DevelopmentThe company's established record in oncology drug development positions it well for discussions around outside development candidates in that category.
Strategic ReviewEPIX's strategic review aims to identify external opportunities to maximize shareholder value, including options like in-licensing external assets and reverse mergers.
Bears Say
Clinical TrialsEPIX announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive mCPRC following an interim analysis that suggested the trial was unlikely to meet the primary endpoint.
Financial PerformanceBased on projected YE25 cash of ~$105M, the price target is being lowered to $2 from $15.
Market ConditionsPoor market conditions can push the stock back to its August lows of ~$4.50 irrespective of the data.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EPIX FAQ
What was ESSA Pharma Inc’s price range in the past 12 months?
ESSA Pharma Inc lowest stock price was $1.40 and its highest was $11.67 in the past 12 months.
What is ESSA Pharma Inc’s market cap?
Currently, no data Available
When is ESSA Pharma Inc’s upcoming earnings report date?
ESSA Pharma Inc’s upcoming earnings report date is Dec 10, 2024 which is in 19 days.
How were ESSA Pharma Inc’s earnings last quarter?
ESSA Pharma Inc released its earnings results on Aug 05, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.086.
Is ESSA Pharma Inc overvalued?
According to Wall Street analysts ESSA Pharma Inc’s price is currently Undervalued.
Does ESSA Pharma Inc pay dividends?
ESSA Pharma Inc does not currently pay dividends.
What is ESSA Pharma Inc’s EPS estimate?
ESSA Pharma Inc’s EPS estimate is -$0.19.
How many shares outstanding does ESSA Pharma Inc have?
ESSA Pharma Inc has 44,368,958 shares outstanding.
What happened to ESSA Pharma Inc’s price movement after its last earnings report?
ESSA Pharma Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -1.907%.
Which hedge fund is a major shareholder of ESSA Pharma Inc?
Among the largest hedge funds holding ESSA Pharma Inc’s share is EntryPoint Capital, LLC. It holds ESSA Pharma Inc’s shares valued at N/A.
---
ESSA Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.85 (4.52% Upside)
$1.85 (4.52% Upside)
Blogger Sentiment
Bullish
EPIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.96%
12-Months-Change
Fundamentals
Return on Equity
-19.83%
Trailing 12-Months
Asset Growth
-13.66%
Trailing 12-Months
Company Description
ESSA Pharma Inc
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
---
EPIX Stock 12 Month Forecast
Average Price Target
$1.85
▲(4.52% Upside)
Technical Analysis
Annovis Bio
―
Corbus Pharmaceuticals
―
Xeris Pharmaceuticals
―
Oncternal Therapeutics
―
---